CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

Condition:   Oropharyngeal Cancer Interventions:   Drug: Cisplatin;   Drug: Durvalumab;   Procedure: Radiotherapy;   Procedure: Dose-escalated radiotherapy Sponsors:   University of Birmingham;   AstraZeneca Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials